A novel brain targeting MnOx-based MI-3 nanoplatform for immunogenic cell death initiated high-efficiency antitumor immunity against orthotopic glioblastoma

Wang, Xuejie; Wang, Zhanfeng; Ma, Ping'an; Liu, Sainan; Wang, Meifang; Chen, Ping; Ding, Binbin; Lin, Jun

doi:10.1016/j.cej.2024.150525

Chemical Engineering Journal

2024

DOI: 10.1016/j.cej.2024.150525

|View full text |Cite

A novel brain targeting MnOx-based MI-3 nanoplatform for immunogenic cell death initiated high-efficiency antitumor immunity against orthotopic glioblastoma

Xuejie Wang,

Zhanfeng Wang,

Ping'an Ma

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent advances in biomimetic strategies for the immunotherapy of glioblastoma

You,

Geng,

et al. 2024

Biomaterials

View full text Add to dashboard Cite

Recent advances in biomimetic strategies for the immunotherapy of glioblastoma

You,

Geng,

et al. 2024

Biomaterials

View full text Add to dashboard Cite

Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy

Wen,

Fu,

Zhang

et al. 2024

J. Am. Chem. Soc.

View full text Add to dashboard Cite

Indoleamine-2,3-dioxygenase-1 (IDO1) pathogenically suppresses immune cell infiltration and promotes tumor cell immune escape by overmetabolizing tryptophan to N-formyl kynurenine in the tumor microenvironment (TME). However, it remains challenging for IDO1 immune checkpoint inhibitors to achieve a significant potency of progression-free survival. Here, we developed a breakthrough in IDO1 inhibition by sono-targeted biobromination reaction using immunostimulating hypobromic-Pphenylperoxydibenzoic acid-linked metallic organic framework nanomedicine (H-MOF NM) to remodel the TME from debrominated hypoxia into hypobromated normoxia and activate the IDO1 immune pathway with in vitro and in vivo remarkable antitumor efficacy. H-MOF NM contains Br + and O − active ingredients with an enlarged band gap to deactivate IDO1 through an innovative biochemical mechanism, taking control over brominating IDO1 amino acid residues at the active sites in the remodeled TME and subsequently activating the immune response, including DC maturation, T-cell activation, and macrophage polarization. Importantly, the H-MOF NM achieves multiple immune responses with high tumor regression potency by combination sono-immunotherapy. This study describes an excellent IDO1 inhibition strategy through the development of immune biobrominative H-MOF nanomedicine and highlights efficient combination immunotherapy for tumor treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A novel brain targeting MnOx-based MI-3 nanoplatform for immunogenic cell death initiated high-efficiency antitumor immunity against orthotopic glioblastoma

Cited by 2 publications

References 32 publications

Recent advances in biomimetic strategies for the immunotherapy of glioblastoma

Recent advances in biomimetic strategies for the immunotherapy of glioblastoma

Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy

Contact Info

Product

Resources

About